Clinical Trial Update: Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating sequential TAS-OX alternating with TAS-IRI plus bevacizumab for late-line metastatic colorectal cancer and is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Rectal Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• TAS-IRI (TAS-IRI)
• TAS-OX (TAS-OX)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Colon Cancer, Rectal Cancer | Phase 2 | Status: RECRUITING